United States:
Escobar One Year Later: Implied Certification And Materiality Under The False Claims Act
23 October 2017
Seyfarth Shaw LLP
To print this article, all you need is to be registered or login on Mondaq.com.
William Eck authored an October 12 article in Bloomberg BNA
Health Care Fraud Report, "Escobar One Year Later: Implied
Certification and Materiality Under the False Claims Act." The
article reviews how Courts have elaborated and applied materiality
inthe context of FCA implied certification since the Escobar
decision. You can read the full aritcle here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
